Hong Kong Stock Movement
CLOUDBREAK-B rose 15.43%. Based on recent news,
<ol>
<li>
On November 28, CLOUDBREAK-B announced that its wholly-owned subsidiary ADS USA successfully obtained patents granted by the Japan Patent Office and the European Patent Office, involving one of the group's core products, CBT-009. This news drove the stock price up, currently reported at HKD 8.15, an increase of 12.26%.
</li>
<li>
On November 27, CLOUDBREAK-B announced that PwC resigned as the company's auditor, and Guowei Certified Public Accountants Co., Ltd. was appointed as the new auditor. This news had a minor impact on the stock price.
</li>
<li>
On November 26, CLOUDBREAK-B shared the latest clinical progress of its candidate drugs CBT-001 and CBT-004 at the Ophthalmology Innovation Summit, showing good safety and efficacy, further boosting market confidence. The biotechnology industry has performed strongly recently, with significant capital inflows.
</li>
</ol>
Stocks with High Trading Volume in the Industry
Innovent Biologics fell 2.55%. Based on recent key news:
<ol>
<li>
On November 25, Innovent Biologics announced that its application for the marketing of high-dose 9mg MaShidu peptide for adult patients with moderate to severe obesity has been accepted by the National Medical Products Administration of China. This news indicates the company's progress in the obesity treatment field, which may have a positive impact on the stock price.
</li>
<li>
On November 24, Morgan Stanley increased its holdings in Innovent Biologics by 1,635,942 shares, raising its ownership ratio to 5.08%. This move shows institutional confidence in Innovent Biologics, which may support the stock price.
</li>
<li>
On November 25, Innovent Biologics was included in the Hang Seng Index, marking the capital market's recognition of its innovative drug capabilities, which may enhance its international influence and stock performance. The globalization trend of the innovative drug industry is evident, with active capital inflows.
</li>
</ol>
Kangfang Biologics fell 1.27%. Based on recent key news:
<ol>
<li>
On November 27, the National Healthcare Security Administration announced that the new version of the medical insurance drug catalog will be released in December, with innovative drugs expected to see rapid volume growth. This policy dividend may boost the market performance of innovative drug companies like Kangfang Biologics.
</li>
<li>
On November 26, the FDA exempted the Phase I clinical trial phase for the drug LY03017, and Luye Pharma plans to advance multi-indication research, which may affect market expectations for related pharmaceutical companies. The release of policy dividends for innovative drugs is drawing market attention.
</li>
</ol>
BeiGene rose 0.59%. Based on recent key news:
<ol>
<li>
On November 27, the National Healthcare Security Administration announced that the new version of the medical insurance drug catalog will be released in December, with innovative drugs expected to see rapid volume growth. This policy dividend is expected to drive the market performance of innovative drug companies like BeiGene.
</li>
<li>
On November 25, BeiGene recorded a large cross-trade transaction, with the stock price 1.9% lower than the previous day's closing price, but net active buying of HKD 69.63 million, indicating market recognition of its long-term value.
</li>
<li>
On November 26, global capital flowed into emerging markets, with foreign capital optimistic about Chinese innovative drug assets, expecting net capital inflows to continue in 2026, driving the rise of the Hong Kong stock innovative drug sector
The innovative drug industry has favorable policies, and capital inflow is significant.
</li>
</ol>
Stocks ranked among the top in industry market capitalization
Kelong Botai Biotechnology-B fell by 0.09%. Based on recent key news:
<ol>
<li>
On November 27, Kelong Botai Biotechnology-B's core product, Lukanasatuzumab, received global recognition and achieved breakthrough progress in Phase III clinical research, driving stock price fluctuations. Zhitong Finance reported that its ADC+IO therapy in collaboration with Merck achieved positive results in the non-small cell lung cancer field, further validating its combination treatment potential.
</li>
<li>
On November 25, JP Morgan raised its revenue forecast for Kelong Botai Biotechnology and increased its target price due to the success of its clinical trials in first-line treatment for non-small cell lung cancer. JP Morgan believes the company holds a leading position in China's biopharmaceutical sector and reiterated its overweight rating.
</li>
<li>
On November 24, Kelong Botai Biotechnology announced that the commercialization process of its core product in China is accelerating, which is expected to bring significant market growth. CITIC Securities set a target price of HKD 592 for the company and maintained a buy rating. The biopharmaceutical sector has been active recently, with noticeable capital inflow
</li>
</ol>

02592

CLOUDBREAK-B rose 15.43%; Innovent Biologics fell 2.55%, with a transaction volume reaching HKD 700 million; CanSino Biologics fell 1.27%, with a transaction volume reaching HKD 462 million; BeiGene rose 0.59%, with a transaction volume reaching HKD 437 million; Kelun-Bio fell 0.09%, with a market capitalization reaching HKD 106.5 billion

Hong Kong stock movement: Dual benefits of patent approval and clinical progress, CLOUDBREAK-B rises 15.43%